Clinical Trials
25
Active:1
Completed:1
Trial Phases
4 Phases
Phase 1:7
Phase 2:12
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 2
12 (48.0%)Phase 1
7 (28.0%)Not Applicable
3 (12.0%)Phase 3
3 (12.0%)A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- Drug: MRG004A plus best supportive careDrug: Placebo plus best supportive care
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT07138846
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT07093970
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Study of MRG007 in Patients With Advanced Solid Tumors
Not Applicable
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 336
- Registration Number
- NCT07066657
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- Drug: MRG003 + PucotenlimabDrug: Gemcitabine, Docetaxel, or Capecitabine
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT06976190
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Phase 3
Recruiting
- Conditions
- Advanced or Metastatic Urothelium Cancer
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai Miracogen Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05754853
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found